Sivakumar Jeyarajan

Dr. Sivakumar Jeyarajan

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2023 in Biosensors
Verified
Journal Article
Open access
PDF file
SJSivakumar Jeyarajan
Sivakumar Jeyarajan
IZIrina X Zhang
Irina X Zhang
PAPeter Arvan
Peter Arvan
SLStephen I. Lentz
Stephen I. Lentz
LSLeslie S Satin
Leslie S Satin
The free calcium (Ca2+) levels in pancreatic beta cell organelles have been the subject of many recent investigations. Under pathophysiological conditions, disturbances in these pools have been linked to altered intracellular communication and cellular dysfunction. To facilitate studies of subcellular Ca2+ signaling in beta cells and, particularly, signaling between the endoplasmic reticulum (ER) and mitochondria, we designed a novel dual Ca2+ sensor which we termed DS-1. DS-1 encodes two stoichiometrically fluorescent proteins within a single plasmid, G-CEPIA-er, targeted to the ER and R-CEPIA3-mt, targeted to mitochondria. Our goal was to simultaneously measure the ER and mitochondrial Ca2+ in cells in real time. The Kds of G-CEPIA-er and R-CEPIA3-mt for Ca2+ are 672 and 3.7 μM, respectively. Confocal imaging of insulin-secreting INS-1 832/13 expressing DS-1 confirmed that the green and red fluorophores correctly colocalized with organelle-specific fluorescent markers as predicted. Further, we tested whether DS-1 exhibited the functional properties expected by challenging an INS-1 cell to glucose concentrations or drugs having well-documented effects on the ER and mitochondrial Ca2+ handling. The data obtained were consistent with those seen using other single organelle targeted probes. These results taken together suggest that DS-1 is a promising new approach for investigating Ca2+ signaling within multiple organelles of the cell.

12 December 2024 in Infectious Disease Reports
Verified
Journal Article
Open access
PDF file
SJSivakumar Jeyarajan
Sivakumar Jeyarajan
SRSukumar Ranjith
Sukumar Ranjith
RVRaja Veerapandian
Raja Veerapandian
KNKalimuthusamy Natarajaseenivasan
Kalimuthusamy Natarajaseenivasan
PCPrahalathan Chidambaram
Prahalathan Chidambaram
AKAnbarasu Kumarasamy
Anbarasu Kumarasamy
Background/Objective: Indwelling intrauterine contraceptive devices (IUDs) have surfaces that facilitate the attachment of Candida spp., creating a suitable environment for biofilm formation. Due to this, vulvovaginal candidiasis (VVC) is frequently linked to IUD usage, necessitating the prompt removal of these devices for effective treatment. In this study, we evaluated the susceptibility of antimicrobial peptides in vitro against biofilm forming, Amphotericin B (MIC50 > 2 mg L−1) resistant Candida krusei and Candida tropicalis isolated from IUD users who had signs of vaginal candidiasis (hemorrhage, pelvic pain, inflammation, itching, and vaginal discharge). Three antimicrobial peptides, namely, epinecidin-1 (epi-1) and its two variants, namely, variant-1 (Var-1) and variant-2 (Var-2), which were reported to have enhanced antibacterial activity were tested against IUD isolates (C. krusei and C. tropicalis) with pathogenic form of Candida albicans as control. Variants of epi-1, namely, Var-1 and Var-2 were created by substituting lysine in the place of histidine and alanine. Methods: The antimicrobial activity was measured using the microbroth dilution method to determine the minimum inhibitory concentration (MIC) of peptides against C. albicans, C. krusei and C. tropicalis. The MIC of each peptide was used for biofilm assay by Crystal violet staining, Scanning Electron Microscopy, and Reactive Oxygen Species (ROS) assay. To find the possible mechanism of anti-biofilm activity by the peptides, their ability to interact with Candida spp. cell membrane proteins such as Exo-β-(1,3)-Glucanase, Secreted Aspartic Proteinase (Sap) 1, and N-terminal Domain Adhesin: Als 9-2 were determined through PatchDock. Results: The MIC values of peptides: epi-1, var-1 and var-2 against C. albicans are 128 μg mL−1, 64 μg mL−1 and 32 μg mL−1, C. tropicalis are 256 μg mL−1, 64 μg mL−1, and 32 μg mL−1 and C. krusei are 128 µg mL−1, 128 µg mL−1 and 64 µg mL−1, respectively. Both the variants outperformed epi-1. Specifically for tested Candida spp., var-1 showed two- to four-fold enhancements and var-2 showed two- to eight-fold enhancements compared to epi-1. Electron microscopy confirmed that the mechanism of action involves pore formation thus inducing reactive oxygen species in Candida spp. cell membrane. Computational analysis showed that the peptides have a high tendency to interact with Candida spp. cell membrane proteins such as Exo-β-(1,3)-Glucanase, Secreted Aspartic Proteinase (Sap) 1, and N-terminal Domain Adhesin: Als 9-2, thereby preventing biofilm formation. Conclusions: The in vitro evidence supports the potential use of epi-1 and its variants to be used as an anti-biofilm agent to coat IUDs in the future for therapeutic purposes.

21 July 2024 in Biotechnology and Applied Biochemistry
Verified
Journal Article
Closed access
SJSivakumar Jeyarajan
Sivakumar Jeyarajan
APAnsu Susan Peter
Ansu Susan Peter
SRSukumar Ranjith
Sukumar Ranjith
ASAswathy Sathyan
Aswathy Sathyan
SDSenbagam Duraisamy
Senbagam Duraisamy
AKAnbarasu Kumarasamy
Anbarasu Kumarasamy

2 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SJSivakumar Jeyarajan
Sivakumar Jeyarajan
AKAnbarasu Kumarasamy
Anbarasu Kumarasamy
To boost the stability and antimicrobial efficacy of the antimicrobial peptide (AMP) epinecidin-1, we previously engineered two variants — variant-1 and variant-2—by substituting alanine and histidine residues with lysine. This modification led to improved structural integrity and antibacterial function. Our current study builds on this foundation by assessing the anti- Candida capabilities of epinecidin-1 and its variants against test organisms Candida albicans, Candida tropicalis , and Candida krusei . Both variants exhibited potent anti- Candida activity, particularly in disrupting biofilm formation. Minimum Inhibitory Concentrations (MICs) were found to be decreased for both variants compared to the original epinecidin-1 peptide, with variant-2 exhibiting the strongest activity. Electron microscopy confirmed that the mechanism of action involves pore formation and the induction of reactive oxygen species in the Candida cell membrane. Computational analysis showed the peptides have a high tendency to interact with the Candida cell membrane proteins like Exo-B-(1,3)-Glucanase, Secreted aspartic proteinase (Sap) 1, and N-terminal domain adhesin: Als 9-2, to prevent biofilm development.

1 February 2019 in Experimental Eye Research
Verified
Journal Article
Open access
AKAnbarasu Kumarasamy
Anbarasu Kumarasamy
SJSivakumar Jeyarajan
Sivakumar Jeyarajan
JCJonathan Cheon
Jonathan Cheon
APAnthony Premceski
Anthony Premceski
ESEric Seidel
Eric Seidel
FGFrank Giblin
Frank Giblin
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the authors. The senior author contacted the journal in a forthright manner, in an effort to preserve the scientific integrity of the literature, after discovering a significant error in the results reported in the article. The authors were recently made aware of a paper by Kim et al. (Nature Commun. 2019) which shows a spirosome structure (the enzyme aldehyde-alcohol dehydrogenase) present in E. coli (Fig. 5a) that is very similar to the structure the authors thought formed when synthetic alpha A crystallin (66-80) peptide was incubated for 24 h with recombinant guinea pig alpha A insert crystallin (see Kumarasamy et al., Figs. 7C and F, and Fig. 9). Subsequent to publication of their report, the authors later found a number of images that showed what appeared to be the same structure present in samples of their presumably purified recombinant guinea pig alpha A insert crystallin which had been incubated without peptide for 24 h. Hence, the authors now conclude that the structures shown in Figs. 7C and F, and Fig. 9 of their article published in this journal are actually due to E. coli contaminant aldehyde-alcohol dehydrogenase. The authors deeply regret this error and any inconvenience it may have caused.

23 January 2025 in Applied Biosciences
Verified
Journal Article
Open access
PDF file
SJSivakumar Jeyarajan
Sivakumar Jeyarajan
IKIndira Kandasamy
Indira Kandasamy
RVRaja Veerapandian
Raja Veerapandian
JJJayasudha Jayachandran
Jayasudha Jayachandran
SCShona Chandrashekar
Shona Chandrashekar
AKAnbarasu Kumarasamy
Anbarasu Kumarasamy
Candida species, normally part of the healthy human flora, can cause severe opportunistic infections when their population increases. This risk is even greater in immunocompromised individuals. Women using intrauterine contraceptive devices (IUDs) are at higher risk for IUD-associated vulvovaginal candidiasis (VVC) because the device provides a surface for biofilm formation. This biofilm formation allows the normal flora to become opportunistic pathogens, leading to symptoms of VVC such as hemorrhage, pelvic pain, inflammation, itching and discharge. VVC is often linked to IUD use, requiring the prompt removal of these devices for effective treatment. This study evaluated the activity of the arginine-rich peptide “protamine” against Candida albicans, Candida tropicalis and Candida krusei isolated from IUD users who had signs of VVC. The antimicrobial activity was measured using the agar disk diffusion and microbroth dilution methods to determine the minimum inhibitory concentration (MIC). The MIC values of protamine against C. albicans, C. tropicalis and C. krusei are 32 μg mL−1, 64 μg mL−1 and 256 μg mL−1, respectively. The determined MIC of protamine was used for a biofilm inhibition assay by crystal violet staining. Protamine inhibited the biofilm formation of the VVC isolates, and its mechanisms were studied through scanning electron microscopy (SEM) and a reactive oxygen species (ROS) assay. The disruption of cell membranes and the induction of oxidative stress appear to be key mechanisms underlying its anti-candidal effects. The results from an in vitro assay support the potential use of protamine as an antibiofilm agent to coat IUDs in the future for protective purposes.